Hamburg, CITY%20STATE%20OF%20HAMBURG1 Active Studies

Myasthenia Gravis Clinical Trials in Hamburg, CITY%20STATE%20OF%20HAMBURG

Find 1 actively recruiting myasthenia gravis clinical trials in Hamburg, CITY%20STATE%20OF%20HAMBURG. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
66
Enrolling

Recruiting Myasthenia Gravis Studies in Hamburg

About Myasthenia Gravis Clinical Trials in Hamburg

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles responsible for breathing and movement. It occurs when communication between nerves and muscles is disrupted. Treatment includes medications that improve neuromuscular transmission and immunosuppressive therapies.

There are currently 1 myasthenia gravis clinical trials recruiting participants in Hamburg, CITY%20STATE%20OF%20HAMBURG. These studies are seeking a combined 66 participants. Research is being sponsored by Kyverna Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myasthenia Gravis Clinical Trials in Hamburg — FAQ

Are there myasthenia gravis clinical trials in Hamburg?

Yes, there are 1 myasthenia gravis clinical trials currently recruiting in Hamburg, CITY%20STATE%20OF%20HAMBURG. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Hamburg?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hamburg research site will contact you about next steps.

Are clinical trials in Hamburg free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hamburg studies also compensate for your time and travel.

What myasthenia gravis treatments are being tested?

The 1 active trials in Hamburg are testing new therapies including novel drugs, biologics, and treatment approaches for myasthenia gravis.

Data updated March 2, 2026 from ClinicalTrials.gov